BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a...
top of page
![aspot-event[1].png](https://static.wixstatic.com/media/a8e651_08c1cd723d6e4635b76fc432b9a555b7~mv2.png/v1/fill/w_49,h_14,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/a8e651_08c1cd723d6e4635b76fc432b9a555b7~mv2.png)
News & Events
News
- Feb 23, 2022
BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety S
BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression...
- Feb 1, 2022
BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
BURLINGTON, Mass. and JERUSALEM, February 1, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
In the Media
- Jan 18, 2022
Non-Drug, Non-Invasive, FDA-Cleared Device to Treat OCD
8-minute video interview with BrainsWay President and CEO, Christopher von Jako providing expertise around Deep TMS as an effective...
- Jan 13, 2022
We Need a Clearer Understanding of Treatment-Resistant Depression, Experts Say
Dr. Aron Tendler, MD, board-certified psychiatrist and Chief Medical Officer of BrainsWay, shares insights around the uncertainty...
- Dec 22, 2021
Transcranial Magnetic Stimulation Shows Promise for Alcohol Addiction
Proof-of-concept research on Deep TMS as a treatment for alcohol dependence, with commentary from Dr. Markus Heilig and Dr. Abraham...
bottom of page